Evidence map›Paper›PMID 39493069›Full record

ArticleCureus2024

Artificial Intelligence Algorithms in Predictive Factors for Hematologic Toxicities During Concurrent Chemoradiation for Cervical Cancer.

Ion Petre, Serban Negru, Radu Dragomir, Anca Bordianu, Izabella Petre, Luciana Marc, Daliborca Cristina Vlad

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ion PetreDepartment of Biostatistics, Victor Babes University of Medicine and Pharmacy, Timisoara, ROU.
Serban NegruDepartment of Medical Oncology, Oncohelp Oncology Center, Timisoara, ROU.
Radu DragomirDepartment of Obstetrics and Gynecology, Victor Babes University of Medicine and Pharmacy, Timisoara, ROU.
Anca BordianuDepartment of Plastic and Reconstructive, Bagdasar-Arseni Emergency Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Izabella PetreDepartment of Obstetrics and Gynecology, Victor Babes University of Medicine and Pharmacy, Timisoara, ROU.
Luciana MarcDepartment of Internal Medicine, Victor Babes University of Medicine and Pharmacy, Timisoara, ROU.
Daliborca Cristina VladDepartment of Pharmacology, Victor Babes University of Medicine and Pharmacy, Timisoara, ROU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most recent research conducted for the International Federation of Gynecology and Obstetrics indicates that, depending on the stage of cervical cancer (CC), several therapies can provide similar overall survival and progression-free survival rates. To determine the hematologic toxicities during concurrent chemotherapy for cervical cancer, we evaluated these two therapies (cisplatin or carboplatin). Hematologic markers have been studied using statistical models and descriptive statistics. Artificial intelligence models were built using the treatment data and all the information gathered from each patient after one or more administrations to forecast the CC stage. The information was gathered from stage III cervical cancer patients and provided by Oncohelp Hospital from the West Region of Romania. Many traditional machine learning techniques, such as naïve Bayes (NB), random forest (RF), decision trees (DTs), and a trained transformer called TabPFN, were used in the current study to obtain the tabular data. The algorithms NB, RF, and DTs yielded the greatest classification score of 100% when it came to cervical cancer prediction. On the other hand, TabPFN demonstrated an accuracy of 88%. The effectiveness of the models was evaluated by computing the computational complexity of traditional machine learning methods. Early detection increases the likelihood of a good prognosis during the precancerous and malignant stages. Being aware of any indications and symptoms of cervical cancer can also help to prevent delays in diagnosis. These hematologic toxicities, which have been demonstrated to grow linearly with lowering hematologic markers below their normal expectations, would significantly impair patients' quality of life.

Indexed as

cervical cancerconcurrent chemoradiationhematologic toxicitieshpvstage iii

Identifiers

PMID39493069
PMCPMC11528638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.